ROBINS HARLAN S sold $10.8M of ADPT
ROBINS HARLAN S (Chief Scientific Officer) sold 492,400 shares of Adaptive Biotechnologies Corp (ADPT) at an average of $21.89 ($21.72–$22.12, $10.78M total) across 2 trades on 2026-07-21 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest fact is the disclosed sale size, execution date, price range, and that it was conducted under a pre-arranged 10b5-1 plan.
Market read
Traders may monitor insider activity, but this specific disclosure is unlikely to change ADPT fundamentals on its own.
What to watch
The article does not state whether other insiders sold/bought around the same window, nor does it provide context on total compensation or prior sale cadence.
Background
The article is an SEC Form 4 insider transaction disclosure for Adaptive Biotechnologies (ADPT).
Ticker impact
Form 4 shows CSO Robins Harlan S sold 492,400 ADPT shares in open-market trades totaling about $10.78M on 2026-07-21.
Near-term impact likely muted; any reaction would be more about overall insider-selling tone than fundamentals.
The filing is a routine SEC Form 4 disclosure, specifies Rule 10b5-1 pre-arranged plan, and provides sale size and price range without any new company-specific operational or financial catalyst.
Market effects
No direct sector read-across; this is company-specific insider transaction data.
None indicated.
None indicated.
Counterpoint
Even with 10b5-1, large insider sales can coincide with personal liquidity needs, but traders may still use it as a risk-management signal if selling accelerates.
Key entities
- issuerAdaptive Biotechnologies Corp
Subject of the Form 4 insider transaction disclosure.
- insiderRobins Harlan S
Chief Scientific Officer who sold shares.
- trading mechanismRule 10b5-1 plan
Indicates the sale was pre-arranged, reducing discretionary-signal strength.
